半乳糖凝集素-3在成人先天性心脏病中的预后价值
该前瞻性队列纳入602例成人先天性心脏病(ACHD)门诊患者,检测半乳糖凝集素-3(Galectin-3)并随访心血管事件。Galectin-3与心功能及不良事件相关,但校正NT-proBNP后关联消失,提示其附加预后价值有限。
要点
- Galectin-3与ACHD患者心功能及不良心血管事件相关。
- 校正NT-proBNP后Galectin-3的预后关联不再显著。
- Galectin-3对常规风险标志物NT-proBNP的附加价值有限。
核心结论
- Galectin-3与ACHD患者的功能状态、心脏功能及不良心血管事件显著相关。
- 校正NT-proBNP后,Galectin-3与主要终点的关联不再显著,附加预后价值有限。
研究设计与样本
- 前瞻性队列研究,纳入2011至2013年连续就诊的602例ACHD门诊患者。
- thaw血清批量检测Galectin-3,591例(98%)有检测值。
- 以143名健康对照重复测量建立参考值与重复性。
主要发现
- 患者中位年龄33(25-41)岁,58%男性,90%为NYHA I级。
- Galectin-3中位值12.7(范围4.2-45.7)ng/mL,7%患者升高。
- Galectin-3与年龄、心脏药物使用、NYHA分级、窦性心律丧失、心脏功能障碍及NT-proBNP正相关。
- 中位随访4.4(IQR 3.9-4.8)年,195例(33%)发生主要终点。
- 单变量分析中Galectin-3与主要终点显著相关(每倍增HR 2.05;95%CI 1.44-2.93,p<0.001)。
临床怎么用
- Galectin-3可作为ACHD患者心功能评估的参考指标之一。
- 在ACHD风险分层中,NT-proBNP仍是更常规且独立的预后标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Galectin-3 is an emerging biomarker for risk stratification in patients with heart failure. This study aims to investigate the release of galectin-3 and its association with cardiovascular events in patients with adult congenital heart disease (ACHD). METHODS: In this prospective cohort study, 602 consecutive patients with ACHD who routinely visited the outpatient clinic were enrolled between 2011 and 2013. Galectin-3 was measured in thaw serum by batch analysis. The association between galectin-3 and a primary endpoint of all-cause mortality, heart failure, hospitalisation, arrhythmia, thromboembolic events and cardiac interventions was investigated using multivariable Cox models. Reference values and reproducibility were established by duplicate galectin-3 measurements in 143 healthy controls. RESULTS: Galectin-3 was measured in 591 (98%) patients (median age 33 (25-41) years, 58% male, 90% New York Heart Association (NYHA) class I). Median galectin-3 was 12.7 (range 4.2-45.7) ng/mL and was elevated in 7% of patients. Galectin-3 positively correlated with age, cardiac medication use, NYHA class, loss of sinus rhythm, cardiac dysfunction and N-terminal pro-B-type natriuretic peptide (NT-proBNP). During a median follow-up of 4.4 (IQR 3.9-4.8) years, the primary endpoint occurred in 195 patients (33%). Galectin-3 was significantly associated with the primary endpoint in the univariable analysis (HR per twofold higher value 2.05; 95% CI 1.44 to 2.93, p<0.001). This association was negated after adjustment for NT-proBNP (HR 1.04; 95% CI 0.72 to 1.49, p=0.848). CONCLUSIONS: Galectin-3 is significantly associated with functional capacity, cardiac function and adverse cardiovascular events in patients with ACHD. Nevertheless, the additive value of galectin-3 to a more conventional risk marker such as NT-proBNP seems to be limited.
引用
- Baggen VJM, van den Bosch AE, Eindhoven JA, et al. Prognostic value of galectin-3 in adults with congenital heart disease. Heart. 2017. PMID: 28942393. doi:10.1136/heartjnl-2017-312070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。